---
title: "Is Grail (GRAL) stock a buy, sell, or hold at under $70?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294588335.md"
description: "The developer of blood-based cancer tests still has a bright future."
datetime: "2026-08-01T18:28:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294588335.md)
  - [en](https://longbridge.com/en/news/294588335.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294588335.md)
generator: "portal-rs"
---

# Is Grail (GRAL) stock a buy, sell, or hold at under $70?

The developer of blood-based cancer tests still has a bright future.

### Related Stocks

- [GRAL.US](https://longbridge.com/en/quote/GRAL.US.md)

## Related News & Research

- [Grail CEO Joshua J. Ofman sells 5,000 common shares for $425,098](https://longbridge.com/en/news/297572646.md)
- [Insider Selling: GRAIL (NASDAQ:GRAL) CFO Sells $671,579.00 in Stock](https://longbridge.com/en/news/297577183.md)
- [BioNTech (BNTX) Halts Cancer Trial, Is The 15% Undervaluation Still Credible?](https://longbridge.com/en/news/297786944.md)
- [Grail grants 55,867 inducement RSUs to 59 new hires under Nasdaq rule 5635(c)(4)](https://longbridge.com/en/news/297952292.md)
- [BCAL Diagnostics Builds Early Cancer Detection Platform as Test Uptake Grows](https://longbridge.com/en/news/297849557.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**